INS and fatty liver disease: Prior research, predominantly conducted in males, has showcased that the activation of the CAR receptor through pharmacological agonists can ameliorate glucose and insulin tolerance and alleviate hepatic steatosis in animals afflicted with metabolic disorders [6,16].